MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/meg.0000000000002982

Медицинская библиотека · European journal of gastroenterology & hepatology · 2025

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

Nguyen-Khac Eric, Merle Philippe, Ben Khadhra Hajer, Giuliana Amaddeo, Decaens Thomas, Uguen Thomas, Blanc Jean-Frédéric, Ganne-Carrie Nathalie, Bouattour Mohamed, Cattan Stéphane, Silvain Christine, Riachi Ghassan, Peron Jean-Marie, Anty Rodolphe, Bronowicki Jean-Pierre, Baron Aurore, Pageaux Georges-Philippe, Loustaud-Ratti Véronique, Oberti Frédéric, Allaire Manon, Manfredi Sylvain, Ben Merabet Yasmina, Ollivier-Hourmand Isabelle, Lequoy Marie, Nousbaum Jean-Baptiste, Gelu-Simeon Moana, Grados Lucien, Nahon Pierre, Costentin Charlotte, Barbare Jean Claude, Ducournau Gérard, Ganry Olivier, CHIEF Cohort Group

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The burden of hepatocellular carcinoma (HCC) increases worldwide. We report the current landscape of HCC, in France.

METHODS

Carcinome HépatocellulaIrE en France (CHIEF) is a national, prospective, observational cohort initiated in 2019 with the aim of including 5000 patients with HCC, with a 5-year follow-up for each. CHIEF Epidemio 2000, is the first global analysis.

RESULTS

In September 2021, 2043 patients were included in 32 centers. We analyzed 1640 patients, 86% men, 68-year-old, BMI 26.8. 70.8% of patients had cirrhosis (MELD score 9, Child-Pugh A in 77.8%, and portal hypertension in 39%. Liver disease was related to alcohol 58.5%, metabolic syndrome 39%, and virus 23.3%. HCC was confirmed by histology in 46.3%. The Milan criteria fulfilled 32.9%, median AFP 39 ng/ml, 5.9% portal thrombosis, and 10.7% metastases. BCLC classes 0, A, B, C, and D were 6.1, 29.8, 28.8, 32.1, and 3.2%, respectively. HCC was detected during a surveillance program in 35.2% associated with better survival (P < 0.001). Median follow-up was 17.76 months (29.1% deaths). The 6, 12, and 18 months overall survival rates were 84.9% (95% CI: 82.8-87), 76.7% (95% CI: 74.2-79.2), 69.3% (95% CI: 66.4-72.3). One-year survival for BCLC 0, A, B, C, and D was at 95.6, 89.7, 81.7, 54.9, and 40%, respectively (P < 0.0001). First-line treatment was curative, locoregional, or systemic in 40.5, 36.2, and 19.2%, with 1-year survival at 92.9, 82.2, and 57.8%, respectively (P < 0.0001). Atezolizumab-bevacizumab yielded a median overall survival of 17.05 months versus nine for TKI (P < 0.0001).

CONCLUSION

In real-life data, metabolic syndrome becomes the second cause of HCC in France. The 1-year survival rates are high for all treatments applied, and Immunotherapy yields similar results than in trials.

Для цитирования: Nguyen-Khac Eric, Merle Philippe, Ben Khadhra Hajer, Giuliana Amaddeo, Decaens Thomas, Uguen Thomas, Blanc Jean-Frédéric, Ganne-Carrie Nathalie, Bouattour Mohamed, Cattan Stéphane, Silvain Christine, Riachi Ghassan, Peron Jean-Marie, Anty Rodolphe, Bronowicki Jean-Pierre, Baron Aurore, Pageaux Georges-Philippe, Loustaud-Ratti Véronique, Oberti Frédéric, Allaire Manon, Manfredi Sylvain, Ben Merabet Yasmina, Ollivier-Hourmand Isabelle, Lequoy Marie, Nousbaum Jean-Baptiste, Gelu-Simeon Moana, Grados Lucien, Nahon Pierre, Costentin Charlotte, Barbare Jean Claude, Ducournau Gérard, Ganry Olivier, CHIEF Cohort Group. Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.. European journal of gastroenterology & hepatology. 2025. DOI: 10.1097/meg.0000000000002982.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.